RNA methylation in hepatocellular carcinoma: from metabolic reprogramming and immune escape mechanisms to small molecule inhibitor development

肝细胞癌中的RNA甲基化:从代谢重编程和免疫逃逸机制到小分子抑制剂的研发

阅读:1

Abstract

Hepatocellular carcinoma (HCC) is a primary liver malignancy characterized by a high mortality rate and unfavorable prognosis. Altered epigenetic modifications have been closely associated with cancer development and tumor immune escape. RNA methylation is a pervasive epigenetic alteration. N6-methyladenosine (m6A), 5-methylcytosine (m5C), N1-methyladenosine (m1A), N7-methylguanosine (m7G), 3-methylcytidine (m3C), pseudouridine (Ψ), and 2'-O-methylation (Nm) are the main types of RNA methylation. Importantly, abnormal RNA modifications in HCC are key drivers in promoting the translation of oncogenic RNA transcripts. This not only provides cancer cells with a growth-promoting edge but also significantly contributes to tumorigenesis, fueling processes such as uncontrolled cell proliferation, invasion, and metastasis. RNA methylation influences metabolic reprogramming, immune cells, and immunological factors by modulating biological processes like RNA splicing, translation, stability, and translocation. Consequently, RNA methylation is pivotal in modulating biological processes including HCC tumor immunity, proliferation, invasion, and metastasis. This paper systematically examines the mechanisms and functions of these seven types of RNA methylations, offering a thorough overview of their roles and probable mechanisms within the HCC tumor microenvironment and immune system. We seek to offer novel insights and ways to enhance the effectiveness of HCC immunotherapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。